8, Akanbi-Onitiri Crescent, Off Eric Moore Road, Surulere, Lagos. Lagos.
Tel: 234-1-5875179, 5874082, 5877689; 90405798
Teva Pharm. Ind. Ltd, P.O. Box 3190, Petah Tikva 49131, Israel.
Dosage Form, Composition & NAFDAC Registration Number (NRN)
Injection (NRN: 04-1359): Each ampoule contains Human chorionic gonadotropin 2500 units or 5000 units as a lyophilised powder.
Pack Size: Chorigon 2500 units: 5 ampoules with 5 ampoules of solvent; Chorigon 5000 units: 5 ampoules with 5 ampoules of solvent.
The action of Human chorionic gonadotropin (HCG) is virtually identical to that of pituitary luteinizing hormone (LH), although HCG appears to have a small degree of follicle-stimulating hormone (FSH) activity as well. It stimulates production of gonadal steroid hormones by stimulating the interstitial cells (Leydig cells) of the testis to produce androgens and the corpus luteum of the ovary to produce progesterone.
Androgen stimulation in the male leads to the development of secondary sex characteristics and may stimulate testicular descent when no anatomical impediment to descent is present. This descent is usually reversible when HCG is discontinued.
During the normal menstrual cycle, LH participates with FSH in the development and maturation of the normal ovarian follicle, while the mid cycle LH surge triggers ovulation. HCG may substitute for LH in this function.
During a normal pregnancy, HCG secreted by the placenta maintains the corpus luteum after LH secretion decreases, supporting continued secretion of oestrogen and progesterone, and preventing menstruation. HCG has no known effect on fat mobilization, appetite or sense of hunger, or body fat distribution.
Prepubertal cryptorchidism not due to anatomic obstruction. In general, Chorigon is thought to induce testicular descent in situations when descent would have occurred at puberty. Chorigon thus may help to predict whether or not orchiopexy will be needed in the future.
Although in some cases, descent following Chorigon administration is permanent, in most cases the response is temporary. Therapy is usually instituted between the ages of 4 and 9 years.
Selected cases of male hypogonadism secondary to pituitary failure. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotrophins.
HCG has not been demonstrated to be an effective adjunctive therapy in the treatment of obesity. There is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or 'normal' distribution of fat, or that it decreases the hunger and discomfort associated with calorie restricted diets.
Known hypersensitivity to chorionic gonadotropin. Precocious puberty, prostatic carcinoma or other androgen-dependent neoplasia.
HCG should be used in conjunction with human menopausal gonadotrophin only by physicians experienced with infertility problems who are familiar with the criteria for patient selection, contra-indications, warnings, precautions and adverse reactions for menotrophins.
When used in conjunction with human menopausal gonadotropin, the following side effects should be considered: Ovarian hyperstimulation, a syndrome of sudden ovarian enlargement, ascites with or without pain, and/or pleural effusion; Rupture of ovarian cysts with resultant haemoperitoneum; Multiple births; Arterial thromboembolism. If the hyperstimulation syndrome occurs, treatment should be discontinued and the patient hospitalized.
Induction of androgen secretion by chorionic gonadotropin may induce precocious puberty in patients treated for cryptorchidism. If signs of precocious puberty occur, therapy should be discontinued. Since androgens may cause fluid retention, chorionic gonadotropin should be used with caution in patients with epilepsy, migraine, asthma, cardiac or renal disease.
Headache, irritability, restlessness, depression, tiredness, oedema, precocious puberty, gynaecomastia and pain at the site of injection.
Dosage & Administration
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. For intramuscular use only.
There is a marked variance of opinion concerning the dosage regimens to be used. Therefore, the regimen employed in any particular case will depend upon the indication for use, the age and weight of the patient and the physician's preference. The following regimens have been advocated by various authorities.
Prepubertal Cryptorchidism not due to Anatomical Obstruction:
Therapy is usually instituted between the ages of 4 and 9 years.
- 4,000 units, 3 times weekly for 3 weeks - 5,000 units every second day for 4 injections
- 15 injections of 500 - 1,000 units over a period of 6 weeks
- 500 units, 3 times weekly for 4 - 6 weeks. If this course of treatment is not successful, another is begun one month later, giving 1,000 units per injection.
Selected Cases of Male Hypogonadism Secondary to Pituitary Failure:
- 500 - 1,000 units, 3 times a week for 3 weeks followed by the same dose twice a week for 3 weeks.
- 4,000 units, 3 times a week for 6-9 months, following which the dosage may be reduced to 2,000 units, 3 times weekly for an additional 3 months.
Induction of Ovulation and Pregnancy:
Induction of ovulation and pregnancy in the anovulatory infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotrophins.
- 5,000 - 10,000 units the day following the last dose of menotrophin.
Method of Administration:
Dissolve the contents of one ampoule of Chorigon in one ampoule of solvent and administer intramuscularly immediately. Any unused reconstituted solution should be discarded.